The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hepatitis B and C Diagnostics-Global Market Insights and Sales Trends 2024
Synopsis
Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.
The global Hepatitis B and C Diagnostics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatitis B and C Diagnostics in various end use industries. The expanding demands from the Immunodiagnostics and Nucleic Acid Test (NAT), are propelling Hepatitis B and C Diagnostics market. Hepatitis B, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hepatitis C segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatitis B and C Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hepatitis B and C Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hepatitis B and C Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatitis B and C Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hepatitis B and C Diagnostics covered in this report include Roche Diagnostics, Abbott, Siemens, Qiagen, Abbott, bioMérieux, Cepheid, Chembio Diagnostics and DiaSorin, etc.
The global Hepatitis B and C Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Diagnostics
Abbott
Siemens
Qiagen
Abbott
bioMérieux
Cepheid
Chembio Diagnostics
DiaSorin
Enzo Life Sciences
Hologic
MedMira
OraSure Technologies
Quest Diagnostics
Quidel Corp
Randox Laboratories
Global Hepatitis B and C Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hepatitis B and C Diagnostics market, Segment by Type:
Hepatitis B
Hepatitis C
Global Hepatitis B and C Diagnostics market, by Application
Immunodiagnostics
Nucleic Acid Test (NAT)
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatitis B and C Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.
The global Hepatitis B and C Diagnostics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatitis B and C Diagnostics in various end use industries. The expanding demands from the Immunodiagnostics and Nucleic Acid Test (NAT), are propelling Hepatitis B and C Diagnostics market. Hepatitis B, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hepatitis C segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatitis B and C Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hepatitis B and C Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hepatitis B and C Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatitis B and C Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hepatitis B and C Diagnostics covered in this report include Roche Diagnostics, Abbott, Siemens, Qiagen, Abbott, bioMérieux, Cepheid, Chembio Diagnostics and DiaSorin, etc.
The global Hepatitis B and C Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Diagnostics
Abbott
Siemens
Qiagen
Abbott
bioMérieux
Cepheid
Chembio Diagnostics
DiaSorin
Enzo Life Sciences
Hologic
MedMira
OraSure Technologies
Quest Diagnostics
Quidel Corp
Randox Laboratories
Global Hepatitis B and C Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hepatitis B and C Diagnostics market, Segment by Type:
Hepatitis B
Hepatitis C
Global Hepatitis B and C Diagnostics market, by Application
Immunodiagnostics
Nucleic Acid Test (NAT)
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatitis B and C Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hepatitis B and C Diagnostics
1.1 Hepatitis B and C Diagnostics Market Overview
1.1.1 Hepatitis B and C Diagnostics Product Scope
1.1.2 Hepatitis B and C Diagnostics Market Status and Outlook
1.2 Global Hepatitis B and C Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hepatitis B and C Diagnostics Market Size by Region (2018-2029)
1.4 Global Hepatitis B and C Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Hepatitis B and C Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hepatitis B and C Diagnostics Market Size (2018-2029)
1.6.1 North America Hepatitis B and C Diagnostics Market Size (2018-2029)
1.6.2 Europe Hepatitis B and C Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Hepatitis B and C Diagnostics Market Size (2018-2029)
1.6.4 Latin America Hepatitis B and C Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Hepatitis B and C Diagnostics Market Size (2018-2029)
2 Hepatitis B and C Diagnostics Market by Type
2.1 Introduction
2.1.1 Hepatitis B
2.1.2 Hepatitis C
2.2 Global Hepatitis B and C Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hepatitis B and C Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Hepatitis B and C Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hepatitis B and C Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hepatitis B and C Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hepatitis B and C Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hepatitis B and C Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hepatitis B and C Diagnostics Revenue Breakdown by Type (2018-2029)
3 Hepatitis B and C Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Immunodiagnostics
3.1.2 Nucleic Acid Test (NAT)
3.2 Global Hepatitis B and C Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hepatitis B and C Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Hepatitis B and C Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hepatitis B and C Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hepatitis B and C Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hepatitis B and C Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hepatitis B and C Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hepatitis B and C Diagnostics Revenue Breakdown by Application (2018-2029)
4 Hepatitis B and C Diagnostics Competition Analysis by Players
4.1 Global Hepatitis B and C Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatitis B and C Diagnostics as of 2022)
4.3 Date of Key Players Enter into Hepatitis B and C Diagnostics Market
4.4 Global Top Players Hepatitis B and C Diagnostics Headquarters and Area Served
4.5 Key Players Hepatitis B and C Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Hepatitis B and C Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche Diagnostics
5.1.1 Roche Diagnostics Profile
5.1.2 Roche Diagnostics Main Business
5.1.3 Roche Diagnostics Hepatitis B and C Diagnostics Products, Services and Solutions
5.1.4 Roche Diagnostics Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Diagnostics Recent Developments
5.2 Abbott
5.2.1 Abbott Profile
5.2.2 Abbott Main Business
5.2.3 Abbott Hepatitis B and C Diagnostics Products, Services and Solutions
5.2.4 Abbott Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 Abbott Recent Developments
5.3 Siemens
5.3.1 Siemens Profile
5.3.2 Siemens Main Business
5.3.3 Siemens Hepatitis B and C Diagnostics Products, Services and Solutions
5.3.4 Siemens Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Qiagen Recent Developments
5.4 Qiagen
5.4.1 Qiagen Profile
5.4.2 Qiagen Main Business
5.4.3 Qiagen Hepatitis B and C Diagnostics Products, Services and Solutions
5.4.4 Qiagen Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Qiagen Recent Developments
5.5 Abbott
5.5.1 Abbott Profile
5.5.2 Abbott Main Business
5.5.3 Abbott Hepatitis B and C Diagnostics Products, Services and Solutions
5.5.4 Abbott Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Abbott Recent Developments
5.6 bioMérieux
5.6.1 bioMérieux Profile
5.6.2 bioMérieux Main Business
5.6.3 bioMérieux Hepatitis B and C Diagnostics Products, Services and Solutions
5.6.4 bioMérieux Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 bioMérieux Recent Developments
5.7 Cepheid
5.7.1 Cepheid Profile
5.7.2 Cepheid Main Business
5.7.3 Cepheid Hepatitis B and C Diagnostics Products, Services and Solutions
5.7.4 Cepheid Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 Cepheid Recent Developments
5.8 Chembio Diagnostics
5.8.1 Chembio Diagnostics Profile
5.8.2 Chembio Diagnostics Main Business
5.8.3 Chembio Diagnostics Hepatitis B and C Diagnostics Products, Services and Solutions
5.8.4 Chembio Diagnostics Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 Chembio Diagnostics Recent Developments
5.9 DiaSorin
5.9.1 DiaSorin Profile
5.9.2 DiaSorin Main Business
5.9.3 DiaSorin Hepatitis B and C Diagnostics Products, Services and Solutions
5.9.4 DiaSorin Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 DiaSorin Recent Developments
5.10 Enzo Life Sciences
5.10.1 Enzo Life Sciences Profile
5.10.2 Enzo Life Sciences Main Business
5.10.3 Enzo Life Sciences Hepatitis B and C Diagnostics Products, Services and Solutions
5.10.4 Enzo Life Sciences Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 Enzo Life Sciences Recent Developments
5.11 Hologic
5.11.1 Hologic Profile
5.11.2 Hologic Main Business
5.11.3 Hologic Hepatitis B and C Diagnostics Products, Services and Solutions
5.11.4 Hologic Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.11.5 Hologic Recent Developments
5.12 MedMira
5.12.1 MedMira Profile
5.12.2 MedMira Main Business
5.12.3 MedMira Hepatitis B and C Diagnostics Products, Services and Solutions
5.12.4 MedMira Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.12.5 MedMira Recent Developments
5.13 OraSure Technologies
5.13.1 OraSure Technologies Profile
5.13.2 OraSure Technologies Main Business
5.13.3 OraSure Technologies Hepatitis B and C Diagnostics Products, Services and Solutions
5.13.4 OraSure Technologies Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.13.5 OraSure Technologies Recent Developments
5.14 Quest Diagnostics
5.14.1 Quest Diagnostics Profile
5.14.2 Quest Diagnostics Main Business
5.14.3 Quest Diagnostics Hepatitis B and C Diagnostics Products, Services and Solutions
5.14.4 Quest Diagnostics Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.14.5 Quest Diagnostics Recent Developments
5.15 Quidel Corp
5.15.1 Quidel Corp Profile
5.15.2 Quidel Corp Main Business
5.15.3 Quidel Corp Hepatitis B and C Diagnostics Products, Services and Solutions
5.15.4 Quidel Corp Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.15.5 Quidel Corp Recent Developments
5.16 Randox Laboratories
5.16.1 Randox Laboratories Profile
5.16.2 Randox Laboratories Main Business
5.16.3 Randox Laboratories Hepatitis B and C Diagnostics Products, Services and Solutions
5.16.4 Randox Laboratories Hepatitis B and C Diagnostics Revenue (US$ Million) & (2018-2023)
5.16.5 Randox Laboratories Recent Developments
6 North America
6.1 North America Hepatitis B and C Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hepatitis B and C Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hepatitis B and C Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hepatitis B and C Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hepatitis B and C Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hepatitis B and C Diagnostics Market Dynamics
11.1 Hepatitis B and C Diagnostics Industry Trends
11.2 Hepatitis B and C Diagnostics Market Drivers
11.3 Hepatitis B and C Diagnostics Market Challenges
11.4 Hepatitis B and C Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
